Journey Medical Corporation DERM
4.42 USD -0.10 (-2.21%)
At closeNov 10, 2026, 4:03 PM EST
4.43 +0.01 +0.23%
After hours · Nov 10, 4:03 PM ET
4.28 Day range 4.55
4.25 52-week range 9.56
- YTD
- -42.67%
- 1 year
- -50.61%
News
globenewswire.com Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026 Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and…
benzinga.com HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
benzinga.com B. Riley Securities Reiterates Buy on Journey Medical, Raises Price Target to $15 B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $12 to $15.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million. LENSAR (NASDAQ:LNSR) shares…
benzinga.com Journey Medical Q2 EPS $(0.01) Beats $(0.02) Estimate, Sales $17.839M Miss $18.366M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 93.75 percent increase over losses of…
benzinga.com Transcript: Journey Medical Q1 2026 Earnings Conference Call 
benzinga.com Journey Medical Q1 EPS $(0.08), Inline, Sales $15.961M Beat $15.948M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 55.56 percent increase over losses of $(0.18) per share from the same…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
benzinga.com Journey Medical Q4 EPS $(0.04) Beats $(0.06) Estimate, Sales $16.079M Miss $18.863M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 31.03 percent. This is a 150 percent decrease over earnings of…- benzinga.com Earnings Scheduled For March 25, 2026
benzinga.com Journey Medical Files $3.75M At-The-Market Common Stock Offering With B. Riley And Lake Street 3,750,000 SHARES OF COMMON STOCKWe have entered into an At Market Issuance Sales Agreement (the "Sales Agreement") with B. Riley Securities, Inc. ("B. Riley") and Lake Street Capital Markets, LLC…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Journey Medical Q3 EPS $(0.09) Misses $(0.04) Estimate, Sales $17.631M Miss $18.854M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.04) by 143.24 percent. This is a 25 percent increase over losses of…- benzinga.com Earnings Scheduled For November 12, 2025
benzinga.com Insights into Journey Medical's Upcoming Earnings - benzinga.com Journey Medical Corporation Releases Pooled Phase 3 Data From Its MVOR-1 And MVOR-2 Trials Evaluating DFD-29 Demonstrating Emrosi's Statistical Superiority Over Oracea And Placebo In Achieving Investigator's Global Assessment Treatment Success And Reducing Inflammatory Lesion Counts FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory…
- benzinga.com HC Wainwright & Co. Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $13 HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $13.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Lake Street Maintains Buy on Journey Medical, Raises Price Target to $13 Lake Street analyst Thomas Flaten maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to $13.
benzinga.com CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday that it will be acquired by global private equity firm Advent in an…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Journey Medical Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $15.009M Beat $14.933M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.10) by 60 percent. This is a 5.88 percent increase over losses of…
- benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com Examining the Future: Journey Medical's Earnings Outlook
benzinga.com B. Riley Securities Maintains Buy on Journey Medical, Raises Price Target to $12 B. Riley Securities analyst Kalpit Patel maintains Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $9 to $12.- benzinga.com Journey Medical's Emrosi Now Covered For 65% Of U.S. Commercial Lives, Up From 29% In May Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to…
- benzinga.com Journey Medical To Join Russell 2000 And Russell 3000 Indexes, Effective After The Close Of U.S. Equity Markets On June 27, 2025 Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Journey Medical Q1 EPS $(0.18) Beats $(0.24) Estimate, Sales $13.14M Beat $12.05M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 25 percent. This is a 66.04 percent increase over losses of…
- benzinga.com Earnings Scheduled For May 14, 2025
benzinga.com Top 3 Health Care Stocks That May Crash In Q2 - benzinga.com Earnings Scheduled For March 26, 2025
- benzinga.com Journey Medical Announces Publication In The Journal Of The American Medical Association - Dermatology Of The Phase 3 Clinical Trial Results Of Emrosi To Treat Rosacea; DFD-29 Achieved The Co-Primary And All Secondary Endpoints With No Significant Safety Issues When Administered Once Daily For 16 Weeks DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Journey Medical Q3 EPS $(0.12) Beats $(0.15) Estimate, Sales $14.63M Beat $14.39M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 115 percent decrease over earnings of $0.80…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com What's Going On With Journey Medical Stock Today? Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug Administration approved its Emrosi drug for the treatment of rosacea.
- benzinga.com Journey Medical Prepares US Launch for FDA-Approved Rosacea Drug Emrosi Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration…
- benzinga.com Journey Medical Presents DFD-29 Data At 44th Fall Clinical Dermatology Conference Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy…
- benzinga.com Lake Street Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9 Lake Street analyst Thomas Flaten initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $9.
- benzinga.com Rodman & Renshaw Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9 Rodman & Renshaw initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $9.
- benzinga.com Journey Medical Q2 2024 GAAP EPS $(0.17) Misses $(0.14) Estimate, Sales $14.855M Beat $13.880M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 63.04 percent increase over losses of…
- benzinga.com Roth MKM Reinstates Buy on Journey Medical, Announces $11 Price Target Roth MKM analyst Jason Wittes reinstates Journey Medical (NASDAQ:DERM) with a Buy and announces $11 price target.
- benzinga.com Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com Journey Medical Q1 2024 Adj EPS $(0.53) Misses $(0.23) Estimate, Sales $13.000M Miss $14.098M Estimate Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.23) by 130.43 percent. The company reported quarterly sales of $13.000…
- benzinga.com Journey Medical Corporation Appoints Joseph Benesch As Chief Financial Officer, Effective April 26, 2024 Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug…